Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NYSE MKT LLC
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Hemispherx Biopharma Inc

+ Add to Watchlist

HEB:US

0.2199 USD 0.0001 0.05%

As of 20:04:05 ET on 01/30/2015.

Snapshot for Hemispherx Biopharma Inc (HEB)

Open: 0.2101 Day's Range: 0.2100 - 0.2200 Volume: 526,856
Previous Close: 0.2200 52wk Range: 0.2100 - 0.4942 1-Yr Rtn: -49.45%

Stock Chart for HEB

No chart data available.
  • HEB:US 0.2199
  • 1D
  • 1M
  • 1Y
0.2200
Interactive HEB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HEB

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.0900
Est. EPS (USD) (12/2014) -
Est. PEG Ratio -
Market Cap (M USD) 43.99
Shares Outstanding (M) 200.03
30 Day Average Volume 956,763
Price/Book (mrq) 1.6156
Price/Sale (ttm) 208.2122
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HEB

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HEB

Hemispherx Biopharma, Inc. is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen, is undergoing clinical trials for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

William A CarterChairman/Pres/CEOThomas K EquelsVice Chair/CFO/Secy/Gen Cnsl
David R StrayerChief Medical Ofcr/Medical DirAdam PascaleChief Accounting Officer
More Company Profile & Key Executives for HEB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil